A new white paper, which is co -authored by Tunley Environmental and Pharmaceutical Company, says that companies must move their sustainability efforts beyond the narrow focus on standards and climate programs only to include biological diversity concerns.
“The implementation of biological diversity funds: the inspection of supply chains” confirms that biological diversity is important not only for environmental and human health but also for industrial flexibility and economic stability. For example, 60 % of the medicines arise from biological sources. However, the actions of the pharmaceutical industry often contribute to the loss of biological diversity – which indicates the future symptom of these sources – causing land degradation, mortar, pollution and destruction of habitats.
The white paper offers the biological diversity boxes of the Supply chain (SCBF), which is a methodology for measuring quantity, detection and mitigating the effects that the product or economic activity has on global biological diversity. This includes looking at such factors as land use and changing land use (for example the transition from forests to agricultural lands); Satisfaction (nutritional excess in water bodies that can cause algae flowers and loss of oxygen); The effects of pollutants on plants, animals and ecosystems; Water stress and disruption of climate related habitats.
One of the main scale, according to the report, is “species. The scale determines the effect on the biological diversity of main environmental change programs (such as the destruction of habitats, fresh water acids, climate change effects, and pollution) as part of the annual affected species.
Authors – Tara Grazie, Senior Scientist and Biodiversity in Environmental Tonley, and Pista A. Bakba, ESG head (environment, social and governance) in Bisak – that the methodology can help inform strategic decisions, such as from the source of the source from; What materials, tools and processes should be used in manufacturing; The location of the supply chain facilities located. SCBF can also support compliance with regulations such as the sustainability of companies in the European Union and to help companies determine where they exist are the largest capabilities to enhance their environmental goals.
While the white paper focuses on the pharmaceutical industry and includes a case study of BesPak, its principles apply to other industries that contain complex supply chains, such as food, clothing, chemical and manufacturing.
